Journal of Clinical Oncology
Articles in this Issue
Comparative efficacy and safety of bisphosphonates and other bone-modifying agents in patients with bone metastases from lung cancer: A systematic review and Bayesian network meta-analysis.
e20006 Background: Bone metastases from lung cancer are common and significantly affect patient quality of life, leading to pain, skeletal-related events...
The broad-spectrum KIT inhibitor NB003 and activity in advanced gastrointestinal stromal tumors (GIST): Updated results from a phase 1 study (NCT04936178).
11517 Background: NB003 is a novel potent and selective oral small-molecule tyrosine kinase inhibitor of KIT. It was designed to inhibit a broad spectrum...
Barriers and facilitators to implementing the clinical trial navigator program: A qualitative analysis.
e23198 Background: The Clinical Trials Navigator (CTN) Program was launched in 2019 to increase enrollment in cancer clinical trials. It is free for all C...
Real world treatment patterns and outcomes in metastatic EGFR mutation–positive NSCLC patients: A retrospective study from a tertiary care cancer center in India.
1582 Background: Lung cancer is the leading cause of cancer related mortality worldwide with Non small lung cancer (NSCLC) constituting the majority of ca...
Clinical prognostic factors associated with progression-free survival in pts with metastatic EGFR-mutant non-small cell lung cancer treated with gefitinib first-line therapy.
e20695 Background: The current standard treatment of Lung Cancer (LC) are third generation tyrosine kinase inhibitors (TKI) targeting tumors with epiderma...
Peri-operative blood transfusion and ovarian cancer survival rates: A systematic review and meta-analysis.
e17552 Background: Ovarian cancer is the most lethal gynecologic tumor, the 5-year survival is less than 40%. Perioperative blood transfusions are a commo...
PD-1 blockade in combination with bevacizumab and nab-paclitaxel for second-line treatment in cancer of unknown primary (Fudan CUP-002): A prospective, single-arm phase II study.
2529 Background: Cancer of unknown primary (CUP), a heterogeneous tumor characterized by histologically confirmed metastases with undefined primary, accou...
Correlation of a senescence-associated gene signature with prognosis in multiple myeloma.
7543 Background: Multiple myeloma (MM), an incurable malignancy of plasma cells, is predominantly a disease of aging. Cellular senescence, a fundamental b...
A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report.
10001 Background: Dinutuximab, irinotecan, temozolomide and GM-CSF (DIT) is widely used in first relapsed/ refractory high-risk neuroblastoma (r/r HRNB),...
ATheNa-Breast: A real-world pilot of an artificial intelligence (AI) chatbot using therapy guidelines to navigate the growing complexity in breast cancer.
e13623 Background: The increasing complexity in the treatment of breast cancer stems from both the rapid pace of approvals of new treatments and discovery...
DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.
7546 Background: In DREAMM-7 (NCT04246047), BVd exhibited a significant improvement in the risk of progression or death vs DVd in pts with RRMM who had ≥1...
Comparative outcomes of transarterial radioembolization in hepatocellular carcinoma patients with large tumor burden (>5 cm) vs. small tumor burden (≤5 cm).
e16333 Background: The impact of tumor size on survival outcomes and adverse events in patients undergoing treatment for liver malignancies remains unclea...
Descriptive epidemiology of Waldenström macroglobulinemia (WM): Demographics, outcomes, and predictors of survival in the US community oncology setting.
7064 Background: WM is a rare, indolent subtype of non-Hodgkin lymphoma (NHL), comprising <2% of annual U.S. NHL cases. Natural history studies and reg...
R-Spondin 3 as an independent biomarker and potential therapeutic target for colon cancer immunotherapy.
e15557 Background: R-spondin 3 (RSPO3) is a potentiator of the Wnt/β-catenin pathway and its dysregulation has been implicated in cancer development. Howe...
Comparison of large language model-processed unstructured clinical data versus manual physician review in breast cancer.
e13593 Background: Recent advancements in Large Language Models (LLMs) have been shown to automate clinical data extraction; however, their feasibility co...
Chimeric antigen receptor T-cell therapy related cardiovascular adverse effects: A National Inpatient Sample study.
e24025 Background: With the expansion of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in hematologic malignancies, significant treatment adverse effec...
OncoKB: Automated annotation of the pathogenicity and treatment implications of germline mutations in cancer.
e22604 Background: The success of PARP inhibitors in BRCA1/2 mutant tumors represents the convergence of germline and somatic molecular profiling as part...
Efficacy and safety data from Ph1b, dose optimization trial of two doses of TH1902 (sudocetaxel zendusortide), a novel SORT1-targeting peptide drug conjugate (PDC), administered weekly vs q3weekly in patients (pts) with advanced ovarian cancer.
e15113 Background: TH1902 is a novel PDC that targets SORT1 receptor, which is highly expressed in many solid tumors, including ovarian cancer (OVC). Via...
A hierarchical clustering approach to dissect behavioral symptoms in early-stage breast cancer (BC).
12036 Background: Fatigue, cognitive impairment, insomnia, anxiety, and depression are cancer-related behavioral symptoms that frequently co-occur and sha...
A large validation study of AI-powered PD-L1 analyzer compared to pathologists’ assessment of PD-L1 expression in lung cancer.
8535 Background: Programmed death ligand 1 (PD-L1) expression is a useful biomarker for immune checkpoint inhibitors in advanced lung cancer. However, pat...
Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation: A secondary analysis based on two prospective studies.
e17516 Background: PIK3CA gene mutations are among the most common driver mutations in cervical cancer (CC), yet therapeutic strategies targeting PIK3CA m...
Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.
e16595 Background: In the ATLAS and ENVISION phase 3 studies (NCT04688931/NCT05243550) patients with low-grade intermediate-risk non-muscle invasive bladd...
MRI concentric partial response pattern as a predictor of pathological complete response in early triple-negative breast cancer treated with Keynote-522 neoadjuvant therapy.
e12603 Background: In early triple-negative breast cancer (TNBC) current treatment involves neoadjuvant chemo-immunotherapy (NAC). Patients with residual...
ADRB2-driven immunosuppression as a novel prognostic indicator and therapeutic avenue following neoadjuvant treatment in colorectal cancer.
e15533 Background: Colorectal cancer (CRC) remains a major global health concern due to its high prevalence and mortality, especially in advanced stages....
Phase 2 study of nivolumab for patients with meningiomas refractory to surgery and radiotherapy with immune-related response criteria.
2084 Background: The majority of meningiomas, which are the most common central nervous system (CNS) tumors, are benign and often cured by surgical resect...